Success Metrics

Clinical Success Rate

93.4%

Based on 57 completed trials

Completion Rate

93%(57/61)

Active Trials

80(46%)

Results Posted

32%(18 trials)

Terminated

4(2%)

Phase Distribution

Ph phase_3

Ph phase_1

36%

Ph phase_2

47%

Ph early_phase_1

Ph not_applicable

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution172 total trials

Early Phase 1First-in-human

13(7.6%)

Phase 1Safety & dosage

63(36.6%)

Phase 2Efficacy & side effects

81(47.1%)

Phase 3Large-scale testing

7(4.1%)

N/ANon-phased studies

8(4.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

79.2%

57 of 72 finished

Non-Completion Rate

20.8%

15 ended early

Currently Active

trials recruiting

Total Trials

174

all time

Status Distribution

Active(94)

Completed(57)

Terminated(15)

Other(8)

Detailed Status

Completed57

Recruiting56

Active, not recruiting24

Not yet recruiting13

Withdrawn11

unknown8

Development Timeline

Analytics

Development Status

Total Trials

174

Active

Success Rate

93.4%

Most Advanced

Phase 3

Trials by Phase

Early Phase 113 (7.6%)

Phase 163 (36.6%)

Phase 281 (47.1%)

Phase 37 (4.1%)

N/A8 (4.7%)

Trials by Status

not_yet_recruiting137%

recruiting5632%

completed5733%

active_not_recruiting2414%

enrolling_by_invitation11%

withdrawn116%

unknown85%

terminated42%

Recent Activity

80 active trials

Showing 5 of 174

recruitingphase_2

Clinical Trials (174)

Showing 20 of 174 trialsScroll for more

NCT06349083Phase 2

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Recruiting

NCT06455293Phase 2

Psilocybin Therapy for Depression in Parkinson's Disease

Recruiting

NCT07721467Phase 2

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

Not Yet Recruiting

NCT06233344Phase 2

Mindfulness-Assisted Psychedelic Therapy

Recruiting

NCT06731621Phase 1

Psilocybin for Treatment-Resistant Depression in Autism

Active Not Recruiting

NCT06001749Phase 2

Psilocybin in Cancer Pain Study

Recruiting

NCT07336238Phase 2

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Active Not Recruiting

NCT06706232Phase 2

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Recruiting

NCT07211438Phase 2

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Recruiting

NCT06801041Phase 2

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Recruiting

NCT05866471Phase 1

The ENHANCE Study: taVNS and Psilocybin

Recruiting

NCT06200155Phase 2

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Recruiting

NCT06299319Phase 1

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

Active Not Recruiting

NCT06355414Phase 1

Psilocybin in Chronic Low Back Pain and Depression

Recruiting

NCT05723276Not Applicable

Psilocybin in Functional Neurological Disorder

Completed

NCT05301608Phase 1

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Recruiting

NCT07610135Phase 1

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Recruiting

NCT06067737Phase 2

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Recruiting

NCT06247839Phase 3

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Recruiting

NCT07703722Phase 3

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

Recruiting

Drug Details

Intervention Type: DRUG
Total Trials: 174